Cancer Research Infection and Cancer: Biology, Therapeutics, and Prevention Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, E.
Right arrow Articles by Hamaguchi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, E.
Right arrow Articles by Hamaguchi, M.
[Cancer Research 60, 2361-2364, May 1, 2000]
© 2000 American Association for Cancer Research

Advances in Brief

The Ras-Mitogen-activated Protein Kinase Pathway Is Critical for the Activation of Matrix Metalloproteinase Secretion and the Invasiveness in v-crk-transformed 3Y11

Enbo Liu, Aye Aye Thant, Fumitaka Kikkawa, Hisashi Kurata, Shinya Tanaka2, Akihiro Nawa, Shigehiko Mizutani, Satoru Matsuda, Hidesaburo Hanafusa3 and Michinari Hamaguchi4

Departments of Obstetrics and Gynecology [E. L., F. K., A. N., S. Mi.] and Molecular Pathogenesis [A. A. T., S. Ma., M. H.], and The Third Internal Medicine [H. K.], Nagoya University School of Medicine, Showaku, Nagoya 466-8550, Japan, and Laboratory of Molecular Oncology, Rockefeller University, New York, New York 10021 [S. T., H. H.]

ABSTRACT

To search for the intracellular signaling pathway critical for the secretion of matrix metalloproteinases (MMP), we studied the effects of dominant negative Ras (S17N Ras) and dominant negative MEK1 (MEK1AA) expression in v-crk-transformed 3Y1. Expression of either S17N Ras or MEK1AA dramatically suppressed the augmented secretion of MMP-2 and MMP-9 in v-crk-transfected 3Y1. Similarly, a Ras farnesyltransferase inhibitor, manumycin A, and a MEK1 inhibitor, U0126, suppressed MMP secretion in a dose-dependent manner, whereas a PI3 kinase inhibitor, wortmannin, could not. In addition, the suppression of MMP secretion by S17N Ras showed good correlation with the inhibition of in vitro invasiveness of the cells. In contrast, expression of dominant negative C3G did not suppress MMP secretion, although it substantially blocked the c-Jun N-terminal kinase activation. Taken together, the Ras-MEK1 pathway, but not the C3G-JNK pathway, seems to play a key role in the activation of MMP secretion and, hence, the invasiveness of v-crk-transformed cells.

Introduction

MMPs5 are a family of proteinase that implicated in multiple physiological and pathological processes (1) . Among MMPs, MMP-2 and MMP-9 (gelatinases A and B) have drawn attention for their implication in tumor invasion and metastasis (2) . Both MMP-2 and MMP-9 are secreted from the cells as inactive zymogens and activated by proteolytic cleavage (3) . A membrane-type MMP, MT1-MMP, has been proposed as an activator of MMP-2 (4) . In human cancer tissues, evidence accumulated suggests that MMPs are secreted from the stromal fibroblastic cells rather than the tumor cells themselves (5) , yet the regulation of MMP secretion in the stromal cells remains largely unclear.

As a model, we have studied MMP secretion in fibroblasts transformed with oncogenes (6) . As we reported, various oncogene products such as v-Src and v-erbB stimulated the secretion and proteolytic activation of MMP-2, suggesting the presence of a common signaling pathway critical for MMP secretion. To obtain more clues, we investigated the signaling pathway critical for the activation of MMP secretion in v-crk-transfected 3Y1 cells. v-Crk is a Mr 47,000 adapter protein, which contains the SH2 and SH3 domains, having been identified as a product of the oncogene encoded by the avian retrovirus CT10 (7) . In v-crk-transformed cells, tyrosine phosphorylation of a limited number of cellular proteins is increased (7) . In addition, v-Crk seems to tightly associate with multiple target molecules, including two guanine nucleotide exchange proteins, C3G and Sos, by its SH3 domain. The binding of Crk with Sos seems to activate the Ras-MAPK pathway similar to Grb2 (8, 9) , whereas its binding to C3G activates JNK in a Ras-independent manner (10, 11) . Thus, two signaling pathways are activated by the SH3-dependent mechanism in v-crk-transformed cells, yet their roles in tumor invasion remain to be clarified. In this study, we show that the Ras-MEK1-MAPK pathway is critical for the augmented secretion of MMP-2 and MMP-9, whereas the C3G-JNK pathway is dispensable for the activation of MMP secretion.

Materials and Methods

Cells and Plasmids.
A rat fibroblast cell line, 3Y1, was cultured as described previously (12) . v-crk plasmid ligated with the pMEXneo vector was transfected into 3Y1 or cotransfected with S17N ras ligated with pMAM2-BSD (Kaken Seiyaku), which contains the mouse mammary tumor virus promoter as described (13) . Drug-resistant colonies were isolated, and cells expressing v-Crk and S17N Ras in the presence of dexamethasone (2 µM) were selected by immunoblotting (10, 13) . The dominant negative C3G (11) and mek1AA were transiently introduced into cells by electroporation method (14) . The mek1AA mutated at S218A and S222A by PCR was ligated into pTRE and pBabepuro vectors.

Assay of MMPs by Zymography.
The activities of MMPs in the conditioned media were assayed by zymography, as described previously (6) .

Immunoblotting.
Immunoblotting with anti-Crk antibody, anti-pan Ras antibody, anti-MMP-2 antibody, anti-MT1-MMP antibody (Fuji Yakuhin Kogyo), anti-PY20H antibody, and anti-active MAPK antibody was performed as described previously (14, 15) .

Analysis of Ras-bound GDP/GTP.
Analysis of Ras-bound GTP was performed as described (16) . Briefly, cells were starved for 24 h in serum-free DMEM. Cells were washed, harvested in permeabilization buffer, and mixed with streptolysin O (final concentration, 0.4 units/ml). Then, labeled with 10 µCi of [{alpha}-32P]GTP (800 Ci/mmol; New England Nuclear) for 10 min, the guanine nucleotides bound to Ras were eluted and analyzed with TLC.

Invasion Assay by Matrigel.
Cells were assayed for their invasiveness by a modified Boyden chamber method (6) . Briefly, conditioned media obtained from 3Y1 were placed in the lower compartment of the chambers. Cells suspended in serum-free DMEM were seeded onto Matrigel-coated filters. After 12 h of incubation, cells invaded to the lower surface of the filters were fixed, stained, and counted.

Results and Discussion

We first examined the gelatinase activity in the conditioned media of 3Y1 and 3Y1 transfected with v-crk (v-Crk3Y1) by zymography, as described in "Materials and Methods." Although 3Y1 secreted trace amounts of MMP-2 and MMP-9 only in zymogen forms, their activities secreted from v-Crk3Y1 increased up to five times higher than that of 3Y1 (Fig. 1ACitation ). In addition, the proteolytically activated form of MMP-2 appeared in the medium of v-Crk3Y1. To confirm these results, we isolated several independent clones of v-Crk3Y1, and all of them showed essentially similar results (Fig. 1ACitation ).



View larger version (47K):
[in this window]
[in a new window]
  		Fig. 1. Characterization of S17N ras-transfected v-Crk3Y1. A, expression of v-Crk (top) and tyrosine phosphorylation of cellular proteins (middle) were examined by immunoblotting. MMP activity of conditioned media was assayed by zymography (bottom). v-Crk, V1, and V2 are independent clones of v-crk-tranformed 3Y1. B, S17N Ras expression in cells incubated with (+) or without (-) dexamethasone for 24 h probed with anti-pan-Ras antibody. C, 3Y1; Ha-Ras, Ha-ras-transformed 3Y1; Vec., control vector-transfected v-Crk3Y1; D/NR1 and D/NR2, S17N ras-transfected v-Crk3Y1. C, the levels of Ras-GDP and Ras-GTP in S17N ras-transfected v-Crk3Y1(D/NR1) with (+) or without (-) dexamethasone treatment was analyzed by TLC. D, tyrosine phosphorylation of cellular proteins in S17N ras-transfected v-Crk3Y1 with (+) or without (-) dexamethasone treatment was probed with anti-phosphotyrosine antibody. E, activated MAPKs (Erk 1 and 2) were probed with anti-phospho-MAPK. F, expression of Erk2 was probed with anti-Erk2.

 
To study the role of Ras signaling in v-Crk-dependent activation of MMP secretion, we established v-Crk3Y1 cell lines transfected with conditionally inducible S17N ras. Expression of S17N Ras, a mutant Ras with Asn substitution for Ser at position 17 of RasH, was shown to yield a dominant inhibitory effect on endogenous Ras (17) . Under the control of mouse mammary tumor virus promoter/enhancer, S17N ras was induced by treatment with dexamethasone (Fig. 1BCitation ). Because S17N Ras has a suppressive effect on cell growth, we used this conditionally inducible system to avoid the clonal difference of isolated clones. Among several clones isolated, two clones that responded well to the drug were used throughout the study. We confirmed that the Ras-bound GTP:GDP ratio was dramatically decreased by dexamethasone treatment in these cells (Fig. 1CCitation ). In contrast, dexamethasone treatment of S17N ras-transfected v-Crk3Y1 did not show gross inhibitory effect on tyrosine phosphorylation of cellular proteins (Fig. 1DCitation ). We found, however, that activation of MAPKs was strongly inhibited by the expression of S17N Ras (Fig. 1, E and F)Citation .

With these cell lines, we investigated the role of Ras signaling in MMP secretion. We found that expression of S17N Ras by treatment with dexamethasone dramatically suppressed the secretion of MMP-2 and MMP-9 in S17N ras-transfected v-Crk3Y1 (Fig. 2ACitation ). In addition, the activated form of MMP-2 became undetectable by treatment with dexamethasone. In contrast, augmented secretion of MMPs, as well as proteolytic activation of MMP-2, was not suppressed by dexamethasone treatment in the pMAM2-BSD-transfected cells (Fig. 2)Citation . Suppression of MMP secretion by S17N Ras was further confirmed by immunoblotting with anti-MMP-2 and anti-MMP-9 (Fig. 2, B and C)Citation . Interestingly, we found that intracellular levels of MMP-2 and MMP-9 were not grossly increased by v-Crk transformation or suppressed by S17N Ras expression (Fig. 2, D and E)Citation . In addition, intracellular levels of MT1-MMP, which catalyzes proteolytic activation of MMP-2, slightly increased by v-Crk transformation but did not decrease by S17N Ras expression (Fig. 2FCitation ). These results suggest that the Ras pathway is required for the secretion of MMPs but is not critical for the MT1-MMP production in v-Crk3Y1.



View larger version (54K):
[in this window]
[in a new window]
  		Fig. 2. MMP secretion in S17N ras-transfected v-Crk3Y1. Conditioned media of cells treated with (+) or without (-) dexamethasone were subjected to gelatin zymography (A) and immunoblotting with anti-MMP-9 (B) or anti-MMP-2 antibody (C). Intracellular levels of MMP-9 (D), MMP-2 (E), and MT1-MMP (F) in these cells were assayed by immunoblotting with specific antibodies. G, the invasive ability of S17N ras-transfected v-Crk3Y1 treated with (+) or without (-) dexamethasone was assayed by a modified Boyden chamber method. Cells invaded to the lower surface of the Matrigel filters were fixed, stained, and counted. Experiments were carried out in triplicate and repeated three times. Average values ± SD of a typical experiment are shown. C, 3Y1 as control; v-Crk, v-crk-transformed 3Y1; Vec., pMAM2-BSD vector-transfected v-Crk3Y1; D/NR1 and D/NR2, S17N ras-transfected v-Crk3Y1.

 
It should be noted that expression of S17N Ras did not grossly inhibit tyrosine phosphorylation of cellular proteins, including p130Cas and paxillin (data not shown), but suppressed MMP secretion. These results indicate that tyrosine phosphorylation of cellular proteins such as p130Cas is not sufficient but requires downstream signaling via Ras for the activation of MMP secretion.

We next studied whether suppression of MMP secretion by S17N Ras inhibited the invasiveness of cells by the modified Boyden Chamber method, as described in "Materials and Methods." Cells were seeded onto the upper chambers, and cells that penetrated the filters after 12 h of incubation were fixed, stained, and counted. Without dexamethasone treatment, S17N ras-transfected v-Crk3Y1 could penetrate through the reconstituted membrane to the level similar to v-Crk3Y1, whereas 3Y1 could not (Fig. 2GCitation ). In contrast, S17N ras-transfected v-Crk3Y1 significantly lost the invasiveness by treatment with dexamethasone, whereas v-Crk3Y1 transfected with control vector maintained the invasiveness after dexamethasone treatment.

We next studied the role of MEK1, a downstream effector for Ras, in MMP secretion. In the earlier studies, Ras was found to mediate its effects on cellular proliferation by activation of a linear cascade of kinases: Raf, MEK, and MAPK (ERK1/2; Ref. 18 ). Activation of MAPKs in turn regulates the activities of nuclear transcription factors, including Elk-1. However, a large body of evidence accumulated recently suggests that Ras signaling involves a complex array of signaling pathways such as PI3 kinase, RalGDS, SEK-JNK, p120GAP, RIN1, NF1 GAP, and AF6 (18) . In addition to their variety, these effectors seem to have cross-talk, feedback loops and branch points by the multiple components in their downstream (18) . As a step to identify the critical downstream effector for the activation of MMP secretion, we examined the effect of dominant negative MEK1 (MEK1AA) expression in v-Crk3Y1. In this experiment, two types of vector, pTRE and pBabe, were used to confirm the effect of MEK1AA. Myc-epitope-tagged mek1AA gene was ligated into these vectors and introduced into v-Crk3Y1 by electroporation, as described in "Materials and Methods" (Fig. 3, A and B)Citation . As shown in Fig. 3CCitation , v-Crk3Y1 had activated MAPK as judged by anti-phospho-MAPK antibody, and this activation of MAPK was suppressed by the expression of MEK1AA. We found that secretion of both MMP-2 and MMP-9 was dramatically suppressed in mek1AA-transfected v-Crk3Y1, whereas control vector-transfected v-Crk3Y1 showed no change in MMP secretion (Fig. 3ECitation ). These results suggest that MEK1 plays a critical role in augmented secretion of MMPs in v-Crk3Y1.



View larger version (55K):
[in this window]
[in a new window]
  		Fig. 3. Effects of dominant negative MEK1AA expression and dominant negative C3G expression on MMP secretion in v-Crk3Y1. v-Crk3Y1 cells were subjected to transient transfection with mek1AA (15 µg) by electroporation method. The cells were incubated with serum-free medium for 24 h. After incubation, cells were harvested and subjected to immunoblotting with anti-Myc monoclonal (9E10; A), anti-MEK1 (B), anti-phospho-MAPKs (C), or anti-Erk2 antibodies (D). Conditioned media of the cells were subjected to zymography (E). Similarly, cells transfected with dominant negative C3G (15 µg) were incubated with serum-free medium. Cells were harvested and subjected to immunoblotting with anti-C3G antibody (F), anti-phospho-stress-activated protein kinase/JNK (G), or anti-stress-activated protein kinase/JNK antibody (H). The conditioned media were subjected to zymography (I). C, 3Y1 cells; v-Crk, v-Crk-transformed 3Y1; Vec., v-Crk3Y1 transfected with pTRE vector alone; pTRE-MEK1AA, v-Crk3Y1 transfected with mek1AA ligated with pTRE vector; pBabe-MEK1AA, v-Crk3Y1 transfected with mek1AA ligated with pBabepuro vector; v-Crk-C3G (Clone 1 and Clone 2), two independent clones of v-Crk3Y1 transfected with dominant negative C3G.

 
We next examined the role of the C3G-JNK pathway for the augmented MMP secretion in v-Crk3Y1 by use of a dominant negative form of C3G. Dominant negative C3G was transiently introduced into v-Crk3Y1, and its expression was monitored by immunoblotting (Fig. 3FCitation ). As reported previously (11) , v-Crk3Y1 had activated JNK detected by anti-phospho-JNK, and this JNK activation was strongly suppressed by the expression of dominant negative C3G (Fig. 3GCitation ). We found that augmented secretion of MMP-2 and MMP-9, as well as proteolytic activation of MMP-2, was not blocked by the expression of dominant negative C3G (Fig. 3ICitation ), suggesting that the C3G-JNK pathway is dispensable for the activation of MMP secretion in v-Crk3Y1.

To confirm these observations, we next examined the effects of various inhibitors on MMP secretion in v-Crk3Y1. When v-Crk3Y1 was pretreated with the indicated doses of manumycin A, a potent inhibitor of Ras farnesyltransferase (19) , secretion of MMP-2 and MMP-9 was suppressed in a dose-dependent manner (Fig. 4ACitation ). Under these conditions, both the expression of v-Crk and the tyrosine phosphorylation of cellular proteins in v-Crk3Y1 were not perturbed by the drug treatment (data not shown). Similarly, v-Crk3Y1 treated with U0126, a potent inhibitor of MEK1, showed suppression in the secretion of MMP-2 and MMP-9 in a dose-dependent manner (Fig. 4BCitation ), whereas v-Crk expression and cellular protein phosphorylation were not inhibited (data not shown). In contrast to these inhibitors, wortmannin, a potent inhibitor of PI3 kinase that is another downstream effector for Ras, did not show suppression on MMP secretion in v-Crk3Y1 (Fig. 4CCitation ).



View larger version (69K):
[in this window]
[in a new window]
  		Fig. 4. Effects of manumycin A, U0126, and wortmannin on MMP secretion in v-Crk3Y1. v-Crk3Y1 cells pretreated with manumycin A, U0126, or wortmannin were incubated with serum-free medium with indicated doses of drugs. After a 16-h incubation, the conditioned media were subjected to zymography. A, v-Crk3Y1 treated with manumycin A. B, v-Crk3Y1 treated with U0126. C, v-Crk3Y1 treated with wortmannin.

 
In summary, we showed for the first time that v-Crk, an adaptor-type oncogene product, activated MMP secretion in a Ras-MEK1-dependent manner. The activation of MMP secretion via the Ras pathway showed good correlation with the invasiveness of the cells, suggesting the critical role of the Ras pathway in tumor invasion. In contrast, suppression of the C3G-JNK-pathway by a dominant negative form of C3G did not inhibit MMP secretion, indicating the C3G-JNK-pathway is dispensable for the activation of MMP secretion and, hence, for the invasion of v-crk-transformed cells. Interestingly, the Ras-MEK1 signaling pathway was not critical for the production of MT1-MMP in 3Y1 transformed with v-crk. A more extensive search for the downstream factor(s) that directly regulates the secretion of MMPs is an important issue to be elucidated.

FOOTNOTES

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported by Grant-in-Aid for COE Research from the Ministry of Education, Science, Sports and Culture, Japan. Back

2 Present address: Laboratory of Molecular and Cellular Pathology, Hokkaido University School of Medicine, N15 W7, Kita-ku, Sapporo 060-8638, Japan. Back

3 Present address: Osaka Bioscience Institute, 6-2-4, Furuedai, Suita, Osaka 565-0874, Japan. Back

4 To whom requests for reprints should be addressed, at Department of Molecular Pathogenesis, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan. Phone: 81-52-744-2462; Fax: 81-52-744-2464; E-mail: mhamagu{at}med.nagoya-u.ac.jp Back

5 The abbreviations used are: MMP, matrix metalloproteinase; Crk, CT10 regulator of kinase; C3G, Crk SH3-binding guanine nucleotide releasing protein; MAP, mitogen-activated protein; MAPK, MAP kinase; Erk, extracellular signal-regulated kinase; MEK, MAPK/Erk kinase; JNK, c-Jun N-terminal kinase; GDP, guanosine 5'-diphosphate; GTP, guanosine 5'-triphosphate. Back

Received 11/22/99. Accepted 3/17/00.

REFERENCES

  1. Werb Z. ECM and cell surface proteolysis: regulating cellular ecology. Cell, 91: 439-442, 1997.[Medline]
  2. Liotta L. A., Steeg P. S., Stetler-Stevenson W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.[Medline]
  3. Stetler-Stevenson W. G., Krutzsch H. C., Wacher M. P., Margulies I. M. K., Liotta L. A. The activation of human type IV collagenase proenzyme. J. Biol. Chem, 264: 1353-1356, 1989.[Abstract/Free Full Text]
  4. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., Seiki M. A matrix metalloproteinase expressed on the surface of invasive cells. Nature (Lond.), 370: 61-65, 1994.[Medline]
  5. Pyke C., Ralfkiaer E., Huhtala P., Hurskainen T., Danø K., Tryggvason K. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancer by in situ hybridization. Cancer Res, 52: 1336-1341, 1992.[Abstract/Free Full Text]
  6. Hamaguchi M., Yamagata S., Thant A. A., Xiao H., Iwata H., Mazaki T., Hanafusa H. Augmentation of metalloproteinase (gelatinase) activity secreted from Rous sarcoma virus-infected cells correlates with transforming activity of src. Oncogene, 10: 1037-1043, 1995.[Medline]
  7. Mayer B. J., Hamaguchi M., Hanafusa H. A novel viral oncogene with structural similarity to phospholipaseC. Nature (Lond.), 332: 272-275, 1988.[Medline]
  8. Matsuda M., Hashimoto Y., Muroya K., Hasegawa H., Kurata T., Tanaka S., Nakamura S., Hattori S. CRK protein binds to two guanine nucleotide-releasing proteins for the Ras family and modulates nerve growth factor-induced activation of Ras in PC12 cells. Mol. Cell. Biol, 14: 5495-5500, 1994.[Abstract/Free Full Text]
  9. Greulich H., Hanafusa H. A role for Ras in v-Crk transformation. Cell Growth Differ, 7: 1443-1451, 1996.[Abstract]
  10. Tanaka S., Ouchi T., Hanafusa H. Downstream of Crk adaptor signaling pathway: activation of Jun kinase by v-Crk through the guanine nucleotide exchange protein C3G. Proc. Natl. Acad. Sci. USA, 94: 2356-2361, 1997.[Abstract/Free Full Text]
  11. Tanaka S., Hanafusa H. Guanine-nucleotide exchange protein C3G activates JNK1 by a Ras-independent mechanism. J. Biol. Chem, 273: 1281-1284, 1998.[Abstract/Free Full Text]
  12. Hamaguchi M., Grandori C., Hanafusa H. Phosphorylation of cellular proteins in Rous sarcoma virus-infected cells: analysis by use of anti-phosphotyrosine antibodies. Mol. Cell. Biol, 8: 3035-3042, 1988.[Abstract/Free Full Text]
  13. Thant A. A., Serbulea M., Kikkawa F., Liu E., Tomota Y., Hamaguchi M. c-Ras is required for activation of the matrix metalloproteinases by concanavalin A in 3Y1 cells. FEBS Lett, 406: 28-30, 1997.[Medline]
  14. Shibata K., Kikkawa F., Nawa A., Thant A. A., Naruse K., Mizutani S., Hamaguchi M. Both focal adhesion kinase and c-Ras are required for the enhanced matrix metalloproteinase 9 secretion by fibronection in ovarian cancer cells. Cancer Res, 58: 900-903, 1998.[Abstract/Free Full Text]
  15. Hamaguchi M., Matsuyoshi N., Ohnishi Y., Gotoh B., Takeichi M., Nagai Y. p60v-src causes tyrosine phosphorylation and inactivation of the N-cadherin-catenin cell adhesion system. EMBO J, 12: 307-314, 1993.[Medline]
  16. Klein N. P., Schneider R. J. Activation of Src family kinases by hepatitis B virus HBx protein and coupled signaling to Ras. Mol. Cell. Biol, 17: 6427-6436, 1997.[Abstract]
  17. Feig A. L., Cooper M. G. Inhibition of NIH 3T3 cell proliferation by a mutant ras protein with preferential affinity for GDP. Mol. Cell. Biol, 8: 3235-3243, 1988.[Abstract/Free Full Text]
  18. Campbell S. L., Khosrvi-Far R., Rossman K. L., Clark G. J., Der C. J. Increasing complexity of Ras signaling. Oncogene, 17: 1395-1413, 1998.[Medline]
  19. Tamanoi F. Inhibitiors of Ras farnesyltransferases. Trends Biochem. Sci, 18: 349-353, 1993.[Medline]



This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
H. Huynh, K. C. Soo, P. K.H. Chow, and E. Tran
Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma
Mol. Cancer Ther., January 1, 2007; 6(1): 138 - 146.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
N. N. MON, S. ITO, T. SENGA, and M. HAMAGUCHI
FAK Signaling in Neoplastic Disorders: A Linkage between Inflammation and Cancer
Ann. N.Y. Acad. Sci., November 1, 2006; 1086(1): 199 - 212.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Tsuda, Y. Makino, T. Iwahara, H. Nishihara, H. Sawa, K. Nagashima, H. Hanafusa, and S. Tanaka
Crk Associates with ERM Proteins and Promotes Cell Motility toward Hyaluronic Acid
J. Biol. Chem., November 5, 2004; 279(45): 46843 - 46850.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
T.T.T. Nguyen, E. Tran, T.H. Nguyen, P.T. Do, T.H. Huynh, and H. Huynh
The role of activated MEK-ERK pathway in quercetin-induced growth inhibition and apoptosis in A549 lung cancer cells
Carcinogenesis, May 1, 2004; 25(5): 647 - 659.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
B. Bedogni, M. S. O'Neill, S. M. Welford, D. M. Bouley, A. J. Giaccia, N. C. Denko, and M. B. Powell
Topical Treatment with Inhibitors of the Phosphatidylinositol 3'-Kinase/Akt and Raf/Mitogen-Activated Protein Kinase Kinase/Extracellular Signal-Regulated Kinase Pathways Reduces Melanoma Development in Severe Combined Immunodeficient Mice
Cancer Res., April 1, 2004; 64(7): 2552 - 2560.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Takino, H. Miyamori, Y. Watanabe, K. Yoshioka, M. Seiki, and H. Sato
Membrane Type 1 Matrix Metalloproteinase Regulates Collagen-Dependent Mitogen-Activated Protein/Extracellular Signal-Related Kinase Activation and Cell Migration
Cancer Res., February 1, 2004; 64(3): 1044 - 1049.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. R. M. Ruhul Amin, M. L. Oo, T. Senga, N. Suzuki, G.-S. Feng, and M. Hamaguchi
SH2 Domain Containing Protein Tyrosine Phosphatase 2 Regulates Concanavalin A-dependent Secretion and Activation of Matrix Metalloproteinase 2 via the Extracellular Signal-regulated Kinase and p38 Pathways
Cancer Res., October 1, 2003; 63(19): 6334 - 6339.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Daneshmand, D. A. E. Parolin, H. W. Hirte, P. Major, G. Goss, D. Stewart, G. Batist, W. H. Miller Jr., S. Matthews, L. Seymour, et al.
A Pharmacodynamic Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 in Metastatic Colorectal Cancer Patients
Clin. Cancer Res., July 1, 2003; 9(7): 2457 - 2464.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
H. Rubin
Complementary approaches to understanding the role of proteases and their natural inhibitors in neoplastic development: retrospect and prospect
Carcinogenesis, May 1, 2003; 24(5): 803 - 816.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
D. Palmieri, S. Poggi, V. Ulivi, G. Casartelli, and P. Manduca
Pro-collagen I COOH-terminal Trimer Induces Directional Migration and Metalloproteinases in Breast Cancer Cells
J. Biol. Chem., January 31, 2003; 278(6): 3639 - 3647.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. K. S. Shum, J. A. Melendez, and J. J. Jeffrey
Serotonin-induced MMP-13 Production Is Mediated via Phospholipase C, Protein Kinase C, and ERK1/2 in Rat Uterine Smooth Muscle Cells
J. Biol. Chem., November 1, 2002; 277(45): 42830 - 42840.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. Pinkas and P. Leder
MEK1 Signaling Mediates Transformation and Metastasis of EpH4 Mammary Epithelial Cells Independent of an Epithelial to Mesenchymal Transition
Cancer Res., August 15, 2002; 62(16): 4781 - 4790.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Zhang, A. A. Thant, K. Machida, Y. Ichigotani, Y. Naito, Y. Hiraiwa, T. Senga, Y. Sohara, S. Matsuda, and M. Hamaguchi
Hyaluronan-CD44s Signaling Regulates Matrix Metalloproteinase-2 Secretion in a Human Lung Carcinoma Cell Line QG90
Cancer Res., July 15, 2002; 62(14): 3962 - 3965.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. Jiang and R. J. Muschel
Regulation of Matrix Metalloproteinase-9 (MMP-9) by Translational Efficiency in Murine Prostate Carcinoma Cells
Cancer Res., March 1, 2002; 62(6): 1910 - 1914.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
Y. Sohara, N. Ishiguro, K. Machida, H. Kurata, A. A. Thant, T. Senga, S. Matsuda, K. Kimata, H. Iwata, and M. Hamaguchi
Hyaluronan Activates Cell Motility of v-Src-transformed Cells via Ras-Mitogen-activated Protein Kinase and Phosphoinositide 3-Kinase-Akt in a Tumor-specific Manner
Mol. Biol. Cell, June 1, 2001; 12(6): 1859 - 1868.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Hayashi, S. Matsuda, K. Machida, T. Yamamoto, Y. Fukuda, Y. Nimura, T. Hayakawa, and M. Hamaguchi
Invasion Activating Caveolin-1 Mutation in Human Scirrhous Breast Cancers
Cancer Res., March 1, 2001; 61(6): 2361 - 2364.
[Abstract] [Full Text]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, E.
Right arrow Articles by Hamaguchi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, E.
Right arrow Articles by Hamaguchi, M.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online